The laboratory diagnosis of mucopolysaccharidosis III (Sanfilippo syndrome): A changing landscape (Q38240224)

31 August 2017

title

The laboratory diagnosis of mucopolysaccharidosis III (Sanfilippo syndrome): A changing landscape (English)

1 reference

31 August 2017

1 reference

2

Roberto Giugliani

1 reference

31 August 2017

Olaf A Bodamer

1

1 reference

31 August 2017

Tim Wood

series ordinal

3

1 reference

31 August 2017

publication date

16 July 2014

1 reference

Molecular Genetics and Metabolism

31 August 2017

published in

1 reference

31 August 2017

volume

113

1 reference

31 August 2017

issue

1-2

1 reference

31 August 2017

page(s)

34-41

1 reference

The mucopolysaccharidoses: a success of molecular medicine.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Prevalence of lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Sanfilippo syndrome: a mini-review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Genistein in Sanfilippo disease: a randomized controlled crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Behaviour in mucopolysaccharide disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Sanfilippo B in an elderly female psychiatric patient: a rare but relevant diagnosis in presenile dementia.(Invited comment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

A review and selection of simple laboratory methods used for the study of glycosaminoglycan excretion and the diagnosis of the mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Screening tests for glycosaminoglycans in urine: experience from regional interlaboratory surveys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Mucopolysaccharidoses screening: dimethylmethylene blue versus alcian blue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Reliable detection of mucopolysacchariduria in dried-urine filter paper samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

The quantitative determination of glycosaminoglycans in urine with Alcian Blue 8GX

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

A modified uronic acid carbazole reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Diagnosis of Hurler's syndrome in the hospital laboratory and the determination of its genetic type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

A modified screening test for glycosaminoglycan excretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Diagnosis of mucopolysaccharidoses: how to avoid false positives and false negatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Clinical and laboratorial study of 19 cases of mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Diagnosis of mucopolysaccharidoses in a clinically selected population by urinary glycosaminoglycan analysis: a study of 2,000 urine samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses: an evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

An improved method for glycosaminoglycan analysis by LC-MS/MS of urine samples collected on filter paper

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Glycan-based biomarkers for mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Sulphamidase activity in leucocytes, cultured skin fibroblasts and amniotic cells: diagnosis of the Sanfilippo A syndrome with the use of radiolabelled disaccharide substrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Detection of the Sanfilippo D syndrome by the use of a radiolabeled monosaccharide sulfate as the substrate for the estimation of N-acetylglucosamine-6-sulfate sulfatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Detection of the Sanfilippo type B syndrome using radiolabelled oligosaccharides as substrates for the estimation of alpha-N-acetylglucosaminidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type D (MPS IIID)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease C (MPS III C)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Twelve different enzyme assays on dried-blood filter paper samples for detection of patients with selected inherited lysosomal storage diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Assay of heparan-N-sulfamidase in dried leukocytes impregnated in filter paper: a new tool for the identification of mucopolisaccharidosis IIIA and potentially other lysosomal disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Carrier detection in Sanfilippo syndrome type B: report of six families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Prenatal diagnosis of Sanfilippo syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Prenatal diagnosis of Sanfilippo A syndrome: experience in 35 pregnancies at risk and the use of a new fluorogenic substrate for the heparin sulphamidase assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

New substrates and enzyme assays for the detection of mucopolysaccharidosis III (Sanfilippo Syndrome) types A, B, C, and D by tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Neonatal screening for lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Novel LDLR variants in patients with familial hypercholesterolemia: in silico analysis as a tool to predict pathogenic variants in children and their families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Segregation analysis in a family at risk for the Maroteaux-Lamy syndrome conclusively reveals c.1151G>A (p.S384N) as to be a polymorphism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Performance of in silico analysis in predicting the effect of non-synonymous variants in inherited steroid metabolic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Urinary glycosaminoglycan excretion quantified by an automated semimicro method in specimens conveniently transported from around the globe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Simplified newborn screening protocol for lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Use of tandem mass spectrometry for newborn screening of 6 lysosomal storage disorders in a Korean population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis IVA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

The use of dried blood spot samples in the diagnosis of lysosomal storage disorders--current status and perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

The effect of preparation, storage and shipping of dried blood spots on the activity of five lysosomal enzymes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Digital microfluidics: a future technology in the newborn screening laboratory?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Digital microfluidic platform for multiplexing enzyme assays: implications for lysosomal storage disease screening in newborns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Screening patients referred to a metabolic clinic for lysosomal storage disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Comparison of liquid chromatography-tandem mass spectrometry and sandwich ELISA for determination of keratan sulfate in plasma and urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Mucopolysaccharidosis type IIIB (MPS IIIB) masquerading as a behavioural disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Sanfilippo type A: new clinical manifestations and neuro-imaging findings in patients from the same family in Israel: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Revisiting Mendelian disorders through exome sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Newborn screening for hunter disease: a small-scale feasibility study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Molecular defects in Sanfilippo syndrome type A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Novel mutations in Sanfilippo A syndrome: implications for enzyme function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Identification of molecular defects in Italian Sanfilippo A patients including 13 novel mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Mutational analysis of Sanfilippo syndrome type A (MPS IIIA): identification of 13 novel mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.07.013

10.1016/J.YMGME.2014.07.013

7 January 2021

Identifiers

DOI

1 reference

31 August 2017

1 reference